Pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA EQ) on Wednesday launched a non-exclusive licensing agreement with Gilead Sciences Inc for the manufacturing and the distribution of the investigational medicine Remdesivir to treat COVID-19 patients under an Emergency Use Authorization (EUA) by the US FDA.
Under the terms of the agreement, Cipla has received the manufacturing rights to the Remdesivir API and Finished product and allowed to market the product in 127 countries including India and South Africa under its own brand name. It will receive the manufacturing know-how from Gilead Sciences Inc to manufacture the API and Finished product at a commercial scale.
Cipla's extensive geographical and commercial footprint will help make this therapy accessible to more patients and markets. According to the World Health Organisation (WHO)'s tracker, the number of reported COVID-19 cases has crossed the 4m mark globally.
The FDA's EUA will facilitate broader use of Remdesivir to treat hospitalized patients with severe symptoms of COVID-19 based on available data from two global clinical trials, US National Institute for Allergy and Infectious Diseases' placebo-controlled Phase 3 study in patients with moderate to severe symptoms of COVID-19 and Gilead's global Phase 3 study evaluating Remdesivir in patients with severe disease. Multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of Remdesivir as a potential treatment.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary